Arrowstreet Capital, Limited Partnership Cure Vac N.V. Transaction History

Arrowstreet Capital, Limited Partnership

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$14.73 - $35.25 $240,349 - $575,174	-16,317 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$33.72 - $48.22 $6.7 Million - $9.59 Million	-198,824 Reduced 92.42%	16,317 $560,000
Q3 2021 Nov 12, 2021	BUY	$49.26 - $74.5 $4.53 Million - $6.86 Million	92,030 Added 74.75%	215,141 $11.8 Million
Q2 2021 Aug 13, 2021	BUY	$56.91 - $127.53 $7.01 Million - $15.7 Million	123,111 New	123,111 $9.05 Million

12.2M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $716M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.